Twist Bioscience reports strong Q2 earnings, with sales up 25% YoY to $75.3M and orders increasing by 45%. Gross margin expands to 41%. Fiscal year guidance was raised, and William Blair sees continued growth momentum. Analysts reaffirm Outperform ratings.
Amneal Pharmaceuticals settles $270 million opioid crisis agreement, offering cash and naloxone spray. Boosted by strong Q1 earnings, the company reaffirms fiscal guidance.